================================================================================
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): February 27, 2004
DONLAR CORPORATION
(Exact name of registrant as specified in its charter)
Illinois 000-11472 36-3683785
(State or other jurisdiction (Commission (IRS Employer
of incorporation) File Number) Identification No.)
6502 South Archer Road, Bedford Park, Illinois 60501
Registrant's telephone number, including area code: (708) 563-9200
(Address of principal executive offices) (Zip Code)
(Former name or former address, if changed since last report.)
================================================================================
ITEM 5. OTHER EVENTS
On February 27, 2004, the Company issued the following press release.
BEDFORD PARK, Ill.--February 27, 2004--Donlar Corporation (OTC:DLRC), a world
leader in green chemistry, products and technology, today announced that in
order to assure an uninterrupted flow of products and services, it has filed for
protection under Chapter 11 of the Bankruptcy Code. This action became necessary
to prevent our secured lender from foreclosing on the Company's assets. We
anticipate a short stay in Chapter 11.
The Company wants to further assure our customers, vendors and suppliers as well
as our employees that this action will not in any way jeopardize or have an
adverse effect on the quality and delivery of our products and services.
Larry Koskan, President and CEO, stated: "This action became necessary in order
to preserve the value and integrity of Donlar Corporation".
About Donlar
Donlar Corporation is at the forefront of providing a new class of protein
biopolymers that help customers by providing solutions while satisfying
environmental concerns for the creation of non-toxic products for a wide range
of industrial, agricultural and consumer markets. The Company's non-hazardous,
non-toxic, hypoallergenic, environmentally friendly and biodegradable thermal
polyaspartate (TPA) biopolymers are protected by 191 Company-owned patents. The
Company's initial applications for its products include the markets of oil field
operations, fertilizers, detergents and water treatment. Donlar's beta-protein
biopolymers are manufactured in its 50,000 square foot facility located in Peru,
Illinois. (www.donlar.com)
This press release contains forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934. Actual results could differ materially from those
projected in the forward-looking statements, which involve a number of risks and
uncertainties. The contents of this release should be considered in conjunction
with the risk factors in Donlar Biosyntrex's most recent filings with the
Securities and Exchange Commission on Forms 10-QSB and 10-KSB and current
reports on Form 8-K.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
DONLAR CORPORATION
Dated: March 16, 2004 By: /s/ Larry P. Koskan
-----------------------------------------
Larry P. Koskan, Chief Executive Officer